Cargando…

Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study

BACKGROUND: Norepinephrine (NE) is recommended for children and full-term neonates (born at >37 gestational weeks) with septic shock. Meanwhile, data on the effectiveness of NE in preterm neonates are still limited. This study aimed to evaluate the clinical efficacy of NE in preterm neonates with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Pei, Sun, Yifan, Gong, Xiaohui, Li, Zhiling, Hong, Wenchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106054/
https://www.ncbi.nlm.nih.gov/pubmed/37045542
http://dx.doi.org/10.1136/bmjpo-2022-001804
_version_ 1785026340938842112
author Lu, Pei
Sun, Yifan
Gong, Xiaohui
Li, Zhiling
Hong, Wenchao
author_facet Lu, Pei
Sun, Yifan
Gong, Xiaohui
Li, Zhiling
Hong, Wenchao
author_sort Lu, Pei
collection PubMed
description BACKGROUND: Norepinephrine (NE) is recommended for children and full-term neonates (born at >37 gestational weeks) with septic shock. Meanwhile, data on the effectiveness of NE in preterm neonates are still limited. This study aimed to evaluate the clinical efficacy of NE in preterm neonates with dopamine-resistant shock compared with that in full-term neonates. METHODS: This was a single-centre, retrospective (January 2010–December 2020) cohort study of neonates with persistent shock despite adequate fluid resuscitation and dopamine or dobutamine administration at ≥10 μg/kg/min. Medical records of neonates treated with NE were retrospectively reviewed to collect respiratory and haemodynamic parameters and results of arterial blood gas (ABG) tests before and 8 hours after NE infusion. The effectiveness of NE was assessed using changes in clinical parameters and multiple regression models for mortality among subgroups of preterm and full-term neonates. RESULTS: Ninety-two neonates (76% preterm) who received NE infusion were included in the study. NE infusion was started after a median of 7 hours (IQR 2–19 hours) after shock onset. Among the preterm neonates, the maximum dose of NE infusion was 0.5 (IQR 0.3–1.0) µg/kg/min with a median duration of 45 (IQR 24.0–84.5) hours. Haemodynamic dysfunction was ameliorated with increased blood pressure, decreased heart rate and improved ABG results. Preterm neonates with septic shock tended to have a reduced response to NE; however, preterm neonates with persistent pulmonary hypertension of the newborn tended to have a better response. Thirty-four (37%) neonates died in our cohort. The timing, dose and duration of NE use were not associated with neonatal mortality. CONCLUSIONS: Although using NE effectively improves clinical parameters in preterm neonates with dopamine-resistant shock, our study is underpowered to identify the association between NE infusion and mortality in preterm neonates with dopamine-resistant shock.
format Online
Article
Text
id pubmed-10106054
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101060542023-04-17 Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study Lu, Pei Sun, Yifan Gong, Xiaohui Li, Zhiling Hong, Wenchao BMJ Paediatr Open Neonatology BACKGROUND: Norepinephrine (NE) is recommended for children and full-term neonates (born at >37 gestational weeks) with septic shock. Meanwhile, data on the effectiveness of NE in preterm neonates are still limited. This study aimed to evaluate the clinical efficacy of NE in preterm neonates with dopamine-resistant shock compared with that in full-term neonates. METHODS: This was a single-centre, retrospective (January 2010–December 2020) cohort study of neonates with persistent shock despite adequate fluid resuscitation and dopamine or dobutamine administration at ≥10 μg/kg/min. Medical records of neonates treated with NE were retrospectively reviewed to collect respiratory and haemodynamic parameters and results of arterial blood gas (ABG) tests before and 8 hours after NE infusion. The effectiveness of NE was assessed using changes in clinical parameters and multiple regression models for mortality among subgroups of preterm and full-term neonates. RESULTS: Ninety-two neonates (76% preterm) who received NE infusion were included in the study. NE infusion was started after a median of 7 hours (IQR 2–19 hours) after shock onset. Among the preterm neonates, the maximum dose of NE infusion was 0.5 (IQR 0.3–1.0) µg/kg/min with a median duration of 45 (IQR 24.0–84.5) hours. Haemodynamic dysfunction was ameliorated with increased blood pressure, decreased heart rate and improved ABG results. Preterm neonates with septic shock tended to have a reduced response to NE; however, preterm neonates with persistent pulmonary hypertension of the newborn tended to have a better response. Thirty-four (37%) neonates died in our cohort. The timing, dose and duration of NE use were not associated with neonatal mortality. CONCLUSIONS: Although using NE effectively improves clinical parameters in preterm neonates with dopamine-resistant shock, our study is underpowered to identify the association between NE infusion and mortality in preterm neonates with dopamine-resistant shock. BMJ Publishing Group 2023-04-12 /pmc/articles/PMC10106054/ /pubmed/37045542 http://dx.doi.org/10.1136/bmjpo-2022-001804 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neonatology
Lu, Pei
Sun, Yifan
Gong, Xiaohui
Li, Zhiling
Hong, Wenchao
Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
title Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
title_full Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
title_fullStr Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
title_full_unstemmed Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
title_short Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
title_sort use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
topic Neonatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106054/
https://www.ncbi.nlm.nih.gov/pubmed/37045542
http://dx.doi.org/10.1136/bmjpo-2022-001804
work_keys_str_mv AT lupei useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy
AT sunyifan useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy
AT gongxiaohui useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy
AT lizhiling useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy
AT hongwenchao useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy